摘要
目的:观察阿罗洛尔治疗前后对扩张型心肌病(DCM)患者左心室功能的影响,并对其长期应用的安全性作出初步评价。方法:选择63例DCM伴中或重度心力衰竭(心衰)患者给予常规标准心衰治疗,在使用阿罗洛尔前及12个月后记录观测指标,以纽约心功能分级(NYHA)及二维超声心动图评价心功能。结果:阿罗洛尔治疗12个月后可使部分患者左心室功能得以改善,DCM患者的心率及收缩压双乘积较治疗前显著下降,差异有统计学意义(P<0.001)。左心室收缩末期内径较治疗前显著缩小,差异有统计学意义(P<0.001)。左心室射血分数(LVEF)由治疗前的0.27±0.08增加至治疗后的0.41±0.09,差异有统计学意义(P<0.001)。试验中无因不良反应而终止治疗者。结论:初步的临床试验结果表明,阿罗洛尔治疗12个月后对DCM患者的左心室功能具有一定的改善作用,并具有良好的耐受性。
Objectives： To evaluate the effect of long-term arotinolol therapy on the left ventricular function in patients with idiopathic dilated cardiomyopathy （ IDCM ） , and assess adverse events.
Methods ： Sixty-three patients with IDCM were studied at base this study line, and reveived twelve months therapy with arotinolol. Conventional therapy for patients with IDCM was continued throughout the study, and left ventricular function was assessed by New York Heart Association functional class and two-dimensional echocardiography at both baseline and the end of study. Results： After receiving arotinolol twelve months treatment, patients with IDCM had a significant improvement in left ventricular systolic function, and decrease in left ventricular end-systolic dimension （P 〈 0. 001 ）. The left ventricular ejection fraction （LVEF） significantly increased from 0. 27 ± 0. 08 to 0. 41 ± 0. 09 （ P 〈 0. 001 ） , and no adverse events were founded, which needed to discontinue in this study.
Conclusions：In this preliminary study,the data showed that arotinolol for twelve months treatment had a favorable effect in improving left ventricular function in patients with IDCM, and was generally safe and well tolerable.
出处
《中国循环杂志》
CSCD
北大核心
2008年第2期117-119,共3页
Chinese Circulation Journal
关键词
阿罗洛尔
扩张型心肌病
左心室功能
Arotinolol
Dilated cardiomyopathy
Left ventricular function
